Cytek Biosciences, Inc. Common Stock (CTKB) Stock
Key stats
- Market cap
- $753.32M
- Price / Earnings ratio
- -9.3x
- EPS (TTM)
- -$0.63
- Volume
- Loading
- 52-week high
- $6.34
- 52-week low
- $3.31
Source: third-party data provider, as of November 13, 2026
Compare with CTKB
Recent news

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CTKB

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
CTKB

Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences Q2 Earnings Call Highlights
CTKB

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
CTKB
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 51.90
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.13
- MACD histogram
- -0.03
- SMA 50
- $5.46
- Price above SMA 50
- EMA 50
- $5.47
- Price above EMA 50
- SMA 200
- $4.67
- Price above SMA 200
- EMA 200
- $4.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CTKB

Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
Is the Options Market Predicting a Spike in Cytek Biosciences Bank Stock?
CTKB

Cytek Biosciences Q2 Earnings Call Highlights
Cytek Biosciences Q2 Earnings Call Highlights
CTKB

Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q2 Loss, Tops Revenue Estimates
CTKB

Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
CTKB

CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
CTKB

Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue Estimates
CTKB

Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q4 Loss, Tops Revenue Estimates
CTKB

Why these stocks could lose money even if the market gains
Why these stocks could lose money even if the market gains
CTKB

Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
Investment in procedural medical devices is safer for valuation, says E Squared's Les Funtleyder
CTKB
News tone: automated (AI) classification of the article's content, not a price prediction.
About Cytek Biosciences, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Wenbin Jiang Ph.D. | President, CEO & Chairman of the Board | 1964 |
| Mr. William D. McCombe | Chief Financial Officer | 1958 |
| Dr. Ming Yan Ph.D. | CTO & Director | 1963 |
| Mr. Paul D. Goodson | Head of Investor Relations | — |
| Mr. Ilan B. Feuchtwang | Chief Legal Officer | — |
| Mr. Patrik Sebastian Jeanmonod | Head of Corporate Development Analytics | 1966 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 51.90
- MACD 12/26/9
- 0.10
- EMA 9 of MACD
- 0.13
- MACD histogram
- -0.03
- SMA 50
- $5.46
- Price above SMA 50
- EMA 50
- $5.47
- Price above EMA 50
- SMA 200
- $4.67
- Price above SMA 200
- EMA 200
- $4.97
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $7.00
- Average
- $7.00
- High
- $7.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.9 | -14.8 | ||||||||||
| 2022 | -15.6 | -5.7 | -16.6 | -13.1 | +0.9 | +11.0 | +16.8 | -9.1 | +25.2 | +1.4 | -16.9 | -21.6 |
| 2023 | +19.1 | -16.2 | -3.2 | +29.4 | -33.5 | +4.3 | +8.3 | -14.6 | -28.6 | -22.0 | +64.5 | +27.2 |
| 2024 | -14.9 | -1.4 | -26.7 | -10.3 | -11.6 | +0.9 | +19.6 | -10.5 | +2.8 | -8.2 | +27.8 | -6.2 |
| 2025 | -21.6 | -16.7 | -6.7 | -5.4 | -25.1 | +20.1 | +3.4 | +13.7 | -13.7 | +8.0 | +43.4 | -5.3 |
| 2026 | +1.6 | -13.2 | -1.4 | +1.8 | -9.3 | +4.5 | -7.9 | +10.9 | +29.0 | +5.5 | -0.2 |



